The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Giulia DellavedovaAlessandra DecioLaura FormentiMark R AlbertellaJoanne WilsonAnna D StaniszewskaElisabetta LeoRaffaella GiavazziCarmen GhilardiMaria Rosa BaniPublished in: Cancer research communications (2023)
Selective PARP1i AZD5305 can exceed the efficacy of first-generation PARPi, which target both PARP1 and PARP2, and potentiates the efficacy of CPT when given in combination. AZD5305 alone or in combination with platinum delayed visceral metastasis, ultimately extending the lifespan of OC-PDX-bearing mice. These preclinical models mimic the progression of the disease occurring in patients after debulking surgery, and are translationally relevant.
Keyphrases
- dna damage
- dna repair
- end stage renal disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- insulin resistance
- minimally invasive
- chronic kidney disease
- peritoneal dialysis
- stem cells
- randomized controlled trial
- type diabetes
- patient reported outcomes
- adipose tissue
- metabolic syndrome
- oxidative stress
- phase ii study